MedTrace Logo

Imaging Neuromelanin and Iron in Dystonia/Parkinsonism

NCT03572114 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2018-06-28

No results posted yet for this study

Summary

To generate pilot data to investigate the potential to use in vivo iron- and neuromelanin-quantification as imaging tools for the diagnostic evaluation of movement disorders with predominant dystonia / parkinsonism. To this end we are planning to compare the MR imaging neuromelanin and iron-pattern and content in midbrain, striatum and further brain structures in clinically similar entities and respective, sex- and age-matched healthy controls.

Conditions

  • Sporadic Dystonia
  • Dystonia, Familial
  • Parkinson Disease, Juvenile
  • Neurodegeneration With Brain Iron Accumulation 5
  • Mitochondrial Diseases

Interventions

DIAGNOSTIC_TEST

3Tesla MRI

1. A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content 2. Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes). 3. 1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo) 4. conventional FLAIR sequence

BEHAVIORAL

Burke-Fahn-Marsden Dystonia Rating scale

internationally standardized examination/quantification of dystonia

BEHAVIORAL

MDS-United Parkinsons Disease Rating Scale, Part III

most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society

BEHAVIORAL

Beck Depression Inventory

internationally standardized examination to quantify traits of anxiety and depression

BEHAVIORAL

MoCA: Montreal Cognitive Assessment:

internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Bhatia P Kailash, MD, DM, FRCP · UCL, Institute of Neurology, Sobell Department

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2021-07-01
Completion
2021-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572114 on ClinicalTrials.gov